Jan Anker Jahnsen's picture

Jan Anker Jahnsen

Associate Professor
  • E-mailjan.jahnsen@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2021). Quetiapine, Misuse and dependency: A case-series of questions to a Norwegian network of drug information centers. Drug, Healthcare and Patient Safety. 151-157.
  • Show author(s) (2018). Analysis of questions about use of drugs in breastfeeding to Norwegian drug information centres . International Breastfeeding Journal. 1-9.
  • Show author(s) (2016). A new, simple and robust radioligand binding method used to determine kinetic off-rate constants for unlabeled ligands. Application at α2A- and α2C-adrenoceptors. European Journal of Pharmacology. 113-121.
  • Show author(s) (2013). The C-terminal half of the alpha(2C)-adrenoceptor determines the receptor's membrane expression level and drug selectivity. Naunyn-Schmiedeberg's Archives of Pharmacology. 1031-1040.
  • Show author(s) (2012). The predicted N-terminal signal sequence of the human alpha(2C)-adrenoceptor does not act as a functional cleavable signal peptide. European Journal of Pharmacology. 51-58.
  • Show author(s) (2012). The N-terminal region of the human 5-HT2C receptor has as a cleavable signal peptide. European Journal of Pharmacology. 44-50.
Popular scientific article
  • Show author(s) (2015). Inspirerende foredrag om antibiotikaresistens. Norsk Farmaceutisk Tidsskrift.
Letter to the editor
  • Show author(s) (2014). Perspective on the role of the N-terminal tail of the α2C-adrenoceptor. Naunyn-Schmiedeberg's Archives of Pharmacology. 10-1013.
Doctoral dissertation
  • Show author(s) (2015). Predicted signal peptides, and the role of the N-terminal tail, at the monoamine G-protein coupled receptors 5-HT 2c and a2c.
Academic literature review
  • Show author(s) (2020). Ultrakort om farmakogenetikk. Utposten. 42-43.
  • Show author(s) (2020). Review of questions concerning clinical drug interactions in ADHD treatment from physicians in Norway. Frontiers in Pharmacology.
Website (informational material)
  • Show author(s) (2024). RELIS og kunstig intelligens.
  • Show author(s) (2016). Venlafaksin og risiko for kardiovaskulære bivirkninger.
Article in business/trade/industry journal
  • Show author(s) (2022). Bytte legemidler – hva bør man tenke på? Utposten. 54-55.

More information in national current research information system (CRIStin)